Alexandria Real Estate Equities just delivered one of the sharpest single-session drops in its history. The stock fell nearly 15% on April 28 after Q1 results, closing at $40.41 — down 15.5% on the week and 12.2% over the past month. Headlines this week described it as nearing a 17-year low. The real question now is whether the repricing reflects a temporary reset or a structural re-rating of the life science REIT model.
The earnings call set the tone. Alexandria reaffirmed its $6.40 FFO midpoint for 2026, but the market clearly looked through that headline number. Tenant move-outs are rising. Near-term occupancy is guided toward 87% by year-end — a level that highlights genuine vacancy pressure in its lab campuses. The company is leaning heavily on asset disposals — $2.9 billion targeted — to fund its development pipeline, a plan that adds balance sheet complexity at exactly the wrong moment in the rate cycle. Q1 FFO matched estimates and revenues topped expectations on tenant collections, but those reassurances were not enough to arrest the sell-off.
Short sellers moved quickly to press the position. Short interest climbed 23% in a single week, reaching 4.3% of the free float — and is up 53% over the past month, a sharp build in a name that had not previously attracted significant bearish positioning. The cost to borrow ticked up 44% on the week to 0.52%, though in absolute terms that remains very cheap, well below the level that would suggest a supply crunch in the borrow market. Availability in the lending pool remains ample — there is no sign of squeeze mechanics developing — and the ORTEX short score of 38.5, while drifting higher through the week, ranks only in the 35th percentile of the broader universe. This is a directional short trade building on fundamental concerns, not a crowded technical squeeze.
Options traders had already positioned defensively before the print. The put/call ratio has run near 1.49 since mid-April — close to the 52-week peak of 1.50 hit on April 20 — and stands well above the 20-day average of 1.21. The z-score of 1.2 captures the elevated demand for downside protection that preceded and then accompanied the sell-off. The options market, in other words, was not blindsided.
Analyst coverage reflects a Street that had been turning cautious for weeks before Monday's reaction. JPMorgan had already trimmed its target to $57 in mid-March. BMO Capital downgraded to Market Perform and cut to $52 on March 25. Cantor Fitzgerald, responding directly to the post-earnings print, was the latest to move — maintaining Neutral but slashing its target to $43 from $60 on April 29. Morgan Stanley's Equal-Weight with a $54 target and RBC's Sector Perform at $60 round out a consensus that is universally neutral-to-cautious. The mean price target is now $56.21, implying 39% upside from current levels — a gap that typically reflects either deep value or deteriorating fundamentals, and here the Street is voting for the latter by declining to upgrade. Factor scores reinforce the scepticism: EV/EBIT ranks in the 15th percentile, EPS momentum is weak at the 36th percentile over 30 days, and the analyst recommendation differential is essentially neutral at the 49th percentile.
Peer context sharpens the picture. Healthcare REIT peer DOC also fell on the week, dropping 2.6%, while HR and CHCT both managed modest gains of 1.7% and 2.8% respectively. ARE's 15% weekly decline is therefore not sector-wide contagion — it is stock-specific fallout from a print that raised questions about the pace of leasing recovery and the long-term demand thesis for life science space.
Institutional ownership offers limited near-term support signal. Vanguard added roughly 1.3 million shares in Q1, bringing its stake to nearly 15% of shares outstanding. BlackRock and State Street both added modestly. But these are passive-weight adjustments, not conviction buys — and with the stock now trading well below where those additions were made, the passive flow will not provide a floor on its own. What to watch next is how the $2.9 billion disposal programme progresses: whether Alexandria can sell lab assets at prices that support book value, or whether a discount-to-NAV trade begins to set in across the portfolio.
See the live data behind this article on ORTEX.
Open ARE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
